Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 18/20 | 0.70 |
| ▸ | KDR | P35968 | 18/20 | 0.70 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.56 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.56 |
| ▸ | PRKDC | P78527 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25858424 | 0.92 | RET (0.71) | RETKDRPIK3CDABL1SRC | |
| SCHEMBL24467467 | 0.88 | RET (0.70) | RETKDR | |
| SCHEMBL25858507 | 0.88 | RET (0.69) | RETKDRPIK3CDABL1SRC | |
| SCHEMBL25858381 | 0.88 | RET (0.69) | RETKDR | |
| SCHEMBL25858524 | 0.88 | RET (0.69) | RETKDR | |
| SCHEMBL25858443 | 0.87 | RET (0.70) | RETKDR | |
| SCHEMBL25858435 | 0.87 | RET (0.69) | RETKDR | |
| SCHEMBL25858394 | 0.87 | RET (0.69) | RETKDR | |
| SCHEMBL25858431 | 0.85 | RET (0.70) | RETKDR | |
| SCHEMBL20534732 | 0.82 | RET (1.00) | RETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11680068-B2 | Compounds useful as RET inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680068-B2 | Compounds useful as RET inhibitors | RET, BCR, REL | RET 1/4885KDR 542/4885PIK3CD 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.